Application of liquid biopsies in diagnosis and treatment of epithelial ovarian cancer

doi:10.3760/cma.j.issn.1673422X.2018.02.015

Abstract

TANG Hui-Yun, MO Xiao-Yu, BAI Li-Ping, ZHENG Ai. Application of liquid biopsies in diagnosis and treatment of epithelial ovarian cancer[J]. Journal of International Oncology, 2018, 45(2): 122-125.

［1］ Zhou Y, Bian B, Yuan X, et al. Prognostic value of circulating tumor cells in ovarian cancer: a metaanalysis［J］. PLoS One, 2015, 10(6): e0130873. DOI: 10.1371/journal.pone.0130873. ［2］ Khosravi F, Trainor PJ, Lambert C, et al. Static microarray isolation, dynamic time series classification, capture and enumeration of spiked breast cancer cells in blood: the nanotubeCTC chip［J］. Nanotechnology, 2016, 27(44): 44LT03. DOI: 10.1088/09574484/27/44/44LT03. ［3］ Masuda T, Hayashi N, Iguchi T, et al. Clinical and biological significance of circulating tumor cells in cancer［J］. Mol Oncol, 2016, 10(3): 408417. DOI: 10.1016/j.molonc.2016.01.010. ［4］ Gu Y, Ju C, Li Y, et al. Detection of circulating tumor cells in prostate cancer based on carboxylated graphene oxide modified light addressable potentiometric sensor［J］. Biosens Bioelectron, 2015, 66: 2431. DOI: 10.1016/j.bios.2014.10.070. ［5］ Bu J, Kim YJ, Kang YT, et al. Polyester fabric sheet layers functionalized with graphene oxide for sensitive isolation of circulating tumor cells［J］. Biomaterials, 2017, 125: 111. DOI: 10.1016/j.biomaterials.2017.02.009. ［6］ Obermayr E, SanchezCabo F, Tea MK, et al. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients［J］. BMC Cancer, 2010, 10: 666. DOI: 10.1186/1471240710666. ［7］ Kolostova K, Pinkas M, Jakabova A, et al. Molecular characterization of circulating tumor cells in ovarian cancer［J］. Am J Cancer Res, 2016, 6(5): 973980. ［8］ RomeroLaorden N, Olmos D, Fehm T, et al. Circulating and disseminated tumor cells in ovarian cancer: a systematic review［J］. Gynecol Oncol, 2014, 133(3): 632639. DOI: 10.1016/j.ygyno.2014.03.016. ［9］ Kolostova K, Matkowski R, Jdryka M, et al. The added value of circulating tumor cells examination in ovarian cancer staging［J］. Am J Cancer Res, 2015, 5(11): 33633375. ［10］ Lee M, Kim EJ, Cho Y, et al. Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer［J］. Gynecol Oncol, 2017, 145(2): 361365. DOI: 10.1016/j.ygyno.2017.02.042. ［11］ Kuhlmann JD, Wimberger P, Bankfalvi A, et al. ERCC1positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance［J］. Clin Chem, 2014, 60(10): 12821289. DOI: 10.1373/clinchem.2014.224808. ［12］ Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer［J］. Clin Chem, 2015, 61(1): 112123. DOI: 10.1373/clinchem.2014.222679. ［13］ Thierry AR, El Messaoudi S, Gahan PB, et al. Origins, structures, and functions of circulating DNA in oncology［J］. Cancer Metastasis Rev, 2016, 35(3): 347376. DOI: 10.1007/s105550169629x. ［14］ Kamat AA, Sood AK, Dang D, et al. Quantification of total plasma cellfree DNA in ovarian cancer using realtime PCR［J］. Ann N Y Acad Sci, 2006, 1075: 230234. DOI: 10.1196/annals.1368.031. ［15］ Zachariah RR, Schmid S, Buerki N, et al. Levels of circulating cellfree nuclear and mitochondrial DNA in benign and malignant ovarian tumors［J］. Obstet Gynecol, 2008, 112(4): 843850. DOI: 10.1097/AOG.0b013e3181867bc0. ［16］ Bianchi DW, Chudova D, Sehnert AJ, et al. Noninvasive prenatal testing and incidental detection of occult maternal malignancies［J］. JAMA, 2015, 314(2): 162169. DOI: 10.1001/jama.2015.7120. ［17］ Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer［J］. CA Cancer J Clin, 2011, 61(3): 183203. DOI: 10.3322/caac.20113. ［18］ Dobrzycka B, Terlikowski SJ, Kinalski M, et al. Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers［J］. Ann Oncol, 2011, 22(5): 11331140. DOI: 10.1093/annonc/mdq584. ［19］ Parkinson CA, Gale D, Piskorz AM, et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed highgrade serous ovarian carcinoma: a retrospective study［J］. PLoS Med, 2016, 13(12): e1002198. DOI: 10.1371/journal.pmed.1002198. ［20］ Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early and latestage human malignancies［J］. Sci Transl Med, 2014, 6(224): 224ra24. DOI: 10.1126/scitranslmed.3007094. ［21］ Kuhlmann JD, Schwarzenbach H, Wimberger P, et al. LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival［J］. BMC Cancer, 2012, 12: 325. DOI: 10.1186/1471240712325. ［22］ Christie EL, Fereday S, Doig K, et al. Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with highgrade serous ovarian cancer［J］. J Clin Oncol, 2017, 35(12): 12741280. DOI: 10.1200/JCO.2016.70.4627. ［23］ Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis［J］. J Mol Med (Berl), 2013, 91(4): 431437. DOI: 10.1007/s0010901310206. ［24］ Balaj L, Lessard R, Dai L, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences［J］. Nat Commun, 2011, 2: 180. DOI: 10.1038/ncomms1180. ［25］ Lea J, Sharma R, Yang F, et al. Detection of phosphatidylserinepositive exosomes as a diagnostic marker for ovarian malignancies—a proof of concept study［J］. Oncotarget, 2017, 8(9): 1439514407. DOI: 10.18632/oncotarget.14795. ［26］ Nakamura K, Sawada K, Yoshimura A, et al. Clinical relevance of circulating cellfree microRNAs in ovarian cancer［J］. Mol Cancer, 2016, 15(1): 48. DOI: 10.1186/s1294301605360. ［27］ Miska EA. How microRNAs control cell division, differentiation and death［J］. Curr Opin Genet Dev, 2005, 15(5): 563568. DOI: 10.1016/j.gde.2005.08.005. ［28］ Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer［J］. Cancer Res, 2007, 67(18): 86998707. DOI: 10.1158/00085472.CAN071936. ［29］ Taylor DD, GercelTaylor C. MicroRNA signatures of tumorderived exosomes as diagnostic biomarkers of ovarian cancer［J］. Gynecol Oncol, 2008, 110(1): 1321. DOI: 10.1016/j.ygyno.2008.04.033. ［30］ Au Yeung CL, Co NN, Tsuruga T, et al. Exosomal transfer of stromaderived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1［J］. Nat Commun, 2016, 7: 11150. DOI: 10.1038/ncomms11150. ［31］ Yan X, Yin J, Yao H, et al. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer［J］. Cancer Res, 2010, 70(4): 16161624. DOI: 10.1158/00085472.CAN093215.

[1]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[2]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui. Research progress of Nrf2 in ovarian cancer [J]. Journal of International Oncology, 2023, 50(8): 493-497.
[3]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[4]	Yang Lirong, Wang Yufeng. Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer [J]. Journal of International Oncology, 2023, 50(4): 220-226.
[5]	Zhuang Weitao, Qiao Guibin. Research and application of liquid biopsy based on epigenetic markers in the diagnosis and treatment of solid tumors [J]. Journal of International Oncology, 2021, 48(6): 358-361.
[6]	Li Chenxi, Zhao Hongwei. Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors [J]. Journal of International Oncology, 2021, 48(3): 180-183.
[7]	Li Zhefeng, Li Jie, Zhao Xiaoting, Yue Wentao. GLDC regulates proliferation and apoptosis of ovarian cancer cells through PI3K/Akt/mTOR pathway [J]. Journal of International Oncology, 2021, 48(12): 716-722.
[8]	Zheng Jing, Yao Sheng, Shen Wenjie, Sun Zhijia, Zhao Hui, Fu Yan, Gao Ke, Du Nan. Clinical study of intraperitoneal infusion of bevacizumab combined with albumin paclitaxel and carboplatin in carcinomatous peritoneal adhesion from ovarian cancer [J]. Journal of International Oncology, 2021, 48(11): 660-665.
[9]	Yang Lifen, Song Wei, Xu Dawei, Wu Jun, Gao Ran. Mechanisms of miR-103a-3p/CHI3L1 in proliferation and vascular mimicry of ovarian cancer cells [J]. Journal of International Oncology, 2020, 47(6): 333-339.
[10]	Xue Chen, Zhao Yue, Shi Guang, Tang Yan. Research progress of PD-1/PD-L1 inhibitors in ovarian cancer [J]. Journal of International Oncology, 2020, 47(5): 312-315.
[11]	Tian Linghan, Zhu Ling, Liu Xin, Ye Jingwen, He Jiahui, Wang Xicai. Level of peripheral blood circulating tumor cells in lung cancer patients detected by CI-101 and its clinical significance [J]. Journal of International Oncology, 2020, 47(4): 199-204.
[12]	Yang Yiting, Cheng Zhongping. The role of inflammatory cytokines in chemoresistance of epithelial ovarian cancer [J]. Journal of International Oncology, 2020, 47(4): 249-251.
[13]	Fan Yangyang, Wang Ying, Yuan Feng, Du Shanping, He Rongrong, Jia Yan. Study on the mechanism of MALAT1 targeting miR-142-3p in ovarian cancer chemotherapy resistance [J]. Journal of International Oncology, 2020, 47(2): 82-89.
[14]	Quan Ruiquan, Zhang Li, Kuang Li, Li Hongbo, Xiao Meixian. Efficacy of olaparib combined with bevacizumab in the treatment of patients with recurrent platinum-sensitive ovarian cancer and its effect on serum HE4, CA125 and CTC levels [J]. Journal of International Oncology, 2020, 47(10): 606-610.
[15]	Ding Yu, Qiao Guibin. Research progress of liquid biopsy in early diagnosis of lung cancer [J]. Journal of International Oncology, 2019, 46(9): 548-552.

Application of liquid biopsies in diagnosis and treatment of epithelial ovarian cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments